Scott Kachlany, PhD, founder of Actinobac Biomed, Inc.,receives a Thomas Edison Patent of the Year Award from the Research and Development Council of New Jersey and an Innovators Award from the New Jersey Inventors Hall of Fame for his renowned research in discovering new agents in the treatment of leukemias.
Dr. Kachlany, an associate professor of oral biology, microbiology and molecular genetics at Rutgers Dental School of Medicine, discovered the therapeutic uses of Leukothera® during the course of his research at the dental school. His company, Actinobac Biomed, was originally funded with a $500,000 investment in 2009 from Foundation Venture Capital Group (FVCG), LLC. , which invested an additional $100,000 in Actinobac in 2013 to help advance its research.
Loading more stuff…
Hmm…it looks like things are taking a while to load. Try again?